Intellia Therapeutics (NTLA) PT Lowered to $150 at Guggenheim
Tweet Send to a Friend
Guggenheim analyst Debjit Chattopadhyay lowered ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
